Final logo Innovation under Pressure.png
Bio Health sector innovations targeting the SARS-COV-II crisis & Infectious Disease. Industry partnering & licensing, funding, VC & investment, health system needs, & world class solutions. From the lab & the clinic, to the market & the healthcare frontlines.
PROGRAM - Bio Health innovations targeting the SARS-COV-II crisis, future pandemics  & infectious disease. 
Key themes & discussion topics include:
Industry collaborations - what pharma & industry want
Health System innovation needs
Government, grant funding & innovation programs
Venture Capital & investment
Roundtables & workshops 
 

Bio Health sector innovations targeting the SARS-COV-II crisis & Infectious Disease. Industry partnering & licensing, funding, VC & investment, health system needs, & world class solutions. From the lab & the clinic, to the market & the healthcare frontlines.

 

SPEAKERS

Stéphane Hogan.jpeg

Stéphane Hogan

Head of Unit - Health Research, Health and Digital Executive Agency (HaDEA)

Ed Diehl.jpeg

Edward Diehl

Commercialization Officer, Medical Technology Transfer, U.S. Army Medical Research and Development Command

Cedric%20Bisson_edited.jpg

Cedric Bisson

Partner, Teralys Capital, and former co-chair of Canada’s COVID-19 Therapeutics Task Force

Pierre Meulien.jpeg

Pierre Meulien

Executive Director

Innovative Medicines Initiative

Kevin%20Noonan_edited.jpg

Kevin Noonan

Partner, Chair of the Biotechnology &  Pharmaceuticals Practice Group, MBHB LLP

Vince Smeraglia.jpeg

Vince Smeraglia

Executive Director, Office For Research at Rutgers University

Yogikala (Yogi) Prabhu

Technology Transfer and Intellectual Property Office

National Institute of Allergy and Infectious Diseases (NIAID)/NIH

Robin_Grimwood.jpeg

Robin Grimwood

Co-founder & Chief Executive Officer (Interim),

Infinity BiologiX 

Tom Richardson_jfif.webp

Thomas Richardson

Chair, Consortium of Scientists for Pandemic Preparedness,

President, ILSE

Yogi NIAID.jpg
Knaeblein.png
Zinn_edited_edited.jpg
Hans Sauer.jpeg

Joerg Knaeblein

Bayer AG

Research & Development, Pharmaceuticals

Open Innovation, Stranger Things

20141215%20Aseda%20AAB%20headshot_edited

Andrew Bieberich

Senior Scientist,

Aseda Sciences Inc.

Donald Zinn

Vice President US Business,

Crossject

Daniel Martinez.jpg

Daniel Martinez

Co-Founder & CIO,

Copper3D

Hans Sauer

Deputy General Counsel, Vice President for Intellectual Property,

BIO - Biotechnology Innovation Organization

AGENDA

MAY 10

10:00 EST

  • Welcome & Opening Remarks 

    • Christian J. Suojanen - CEO, Broadreach Global

10:05 EST

  • Health and Digital Executive Agency, €20 Billion to rebuild a post-COVID-19 Europe

    • Stéphane Hogan, Head of Unit - Health Research, Health and Digital Executive Agency

10:45 EST

  • Intellectual Property and Covid-19 innovations - Keynote & Panel Discussion

    • Kevin Noonan, Partner, Chair of the Biotechnology &  Pharmaceuticals Practice Group, MBHB LLP

    • Hans Sauer, Deputy General Counsel, VP for IP, BIO - Biotechnology Innovation Organization 

MAY 11

10:15 EST

  • IMI - Public-Private Bio-Pharma innovation in the face of SARS-COV-II 

    • Pierre Meulien, Executive Director, Innovative Medicines Initiative

10:45 EST

  • COVID innovation: global early-stage observations from the vantage point of the COVID-19 Therapeutics Task Force in Canada

    • Cedric Bisson, Partner, Teralys Capital, and former co-chair of Canada’s COVID-19 Therapeutics Task Force

11:15 EST

  • Toxicity risk estimation: an ML classifier trained across pharmaceutical classes applied to antivirals.

    • Andrew Bieberich, Senior Scientist, Aseda Sciences Inc.

MAY 12

10:15 EST

  • Partnering with NIAID- A Technology Transfer perspective.

    • Yogikala (Yogi) Prabhu, Technology Transfer and Intellectual Property Office, NIAID National Institute of Allergy & Infectious Diseases

10:45 EST

  • Copper3D - Antimicrobial Nano-Composites and 3D Printing, from NASA to COVID-19

    • Daniel Martinez, Co-Founder & CIO, 3D Copper

11:15 EST

  • Crossject, ZENEO®️ needle free innovation in vaccine delivery.

    • Donald Zinn, Vice President US Business, Crossject

MAY 13

10:15 EST

  • U.S. Army Medical Research & Development Command: Partner on novel vaccines, therapeutics & technologies.

  • ​Edward Diehl, U.S. Army Medical Research & Development Command: Partner on novel vaccines, therapeutics & technologies.

10:45 EST

  • Call to Action: FAME Consortium - join the Fight Against Mutant Escape

  • Joerg Knaeblein, Bayer AG, Research & Development, Pharmaceuticals,,Open Innovation, Stranger Things

MAY 14

10:15 EST

  • Infinity BiologiX - Innovation Under Pressure: breakthrough crisis response and business scale up.

    • Robin Grimwood, Co-founder & Chief Executive Officer (Interim) 

10:45 EST

  • Call to Action - Join, Partner, Collaborate. The Consortium of Scientists for Pandemic Preparedness

  • Thomas Richardson, Chair, Consortium of Scientists for Pandemic Preparedness, and President, Institute for Life Sciences Entrepreneurship

 
 

Innovation Under Pressure

Session showcase - Watch them Now